40 studies found for:    " February 24, 2010":" March 26, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Conditions: Acquired Immunodeficiency Syndrome;   Infant, Newborn;   Anemia;   Neutropenia;   HIV Infections
Intervention: Drug: cotrimoxazole
22 Recruiting HIV Fat Redistribution and the Evaluation of Brown Fat
Condition: HIV Infections
Intervention:
23 Completed GSK1349572 Relative Bioavailability Study
Condition: HIV Infections
Interventions: Drug: GSK1349572 formulation AP;   Drug: GSK1349572 formulation AW;   Drug: GSK1349572 formulation AX
24 Completed Reducing HIV Risk Among Mexican Youth
Conditions: HIV Infections;   AIDS;   Sexually Transmitted Diseases
Interventions: Behavioral: Adolescent Safer Sex Intervention;   Behavioral: Parent Safer Sex Communication Intervention;   Other: Adolescent Health Promotion Control Condition;   Other: Parent Health Promotion Control Condition
25 Active, not recruiting Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
26 Completed
Has Results
Sustiva Levels With Use of a Gel Capsule
Conditions: HIV;   HIV Infections
Interventions: Drug: Efavirenz;   Drug: Over-encapsulated efavirenz
27 Completed
Has Results
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Condition: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention: Biological: Serostim
28 Completed GSK1349572 Drug Interaction Study With Efavirenz
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Healthy
Interventions: Drug: GSK1349572;   Drug: Efavirenz
29 Completed Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)
Condition: HIV Infection
Intervention:
30 Completed Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
Conditions: HIV;   Cardiovascular Disease
Intervention:
31 Active, not recruiting Observational Data Analysis in EuroSIDA (0518-058)
Condition: HIV-1 Infections
Intervention:
32 Enrolling by invitation " Arthrospira Platensis" as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon
Condition: HIV
Intervention: Dietary Supplement: Arthrospira platensis
33 Active, not recruiting Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network (MK-0518-268)
Condition: HIV-1 Infections
Intervention:
34 Completed Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
Condition: HIV-1
Intervention: Biological: MYM-V101
35 Unknown  A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
Conditions: HIV/AIDS;   STD;   Pregnancy
Intervention: Behavioral: Computer-based parent-adolescent HIV communication
36 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
37 Completed A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
Condition: HIV-1 Infection
Intervention: Drug: Bevirimat
38 Recruiting Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Drug: temsirolimus;   Other: laboratory biomarker analysis
39 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR
40 Completed Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Condition: AIDS
Interventions: Procedure: Blood collection;   Biological: GSK HIV vaccine 732462

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page   
Indicates status has not been verified in more than two years